jili fish casino login app
jili fish casino login app
In world 1st, Belgian sex workers now have access to contracts, benefits and pensionsCONAKRY, Guinea -- Chaos erupted at a soccer game in Guinea after fans protested a referee's call and thousands of panicked spectators tried to flee the stadium, leaving at least 56 people dead in the West African nation, officials and witnesses said Monday. Amid the confusion, security forces used tear gas, local news website Media Guinea reported. Many of the dead were crushed as they tried to escape through the stadium gates, a journalist covering the game for a local sports website told The Associated Press. "The gates, that's where the stampede happened," said Cissé Lancine, who got away by climbing over one of the stadium walls. "I was saved because I did not rush towards the exit." The world's latest sports crowd disaster unfurled Sunday in the second-largest city in a military-run nation where information is sparse and government-controlled at the best of times. It was not immediately clear how much the death toll could grow. Lancine said between 20,000 and 30,000 people were present at the Third of April stadium to watch the local Labe and Nzerekore teams compete in the final of the first national tournament honoring military leader Mamadi Doumbouya. Checkpoints were set up Monday throughout Nzerekore, a city of about 200,000 that was at a standstill as soldiers guarded the hospital where victims were being treated. Most shops were closed. Video, apparently from the scene, showed shouting fans protesting the refereeing. People ran as they tried to escape the stadium, many of them jumping the high fence. "Supporters threw stones. This is why the security services used tear gas," reported Media Guinea, which also wrote that several of the dead were children and some of the injured were in critical condition. The footage showed people lying on the floor of a hospital as members of a crowd helped the wounded. Enock Loua, a resident of Nzerekore, learned over the phone that his niece Aline Olivier had been killed. "We have a hard time realizing what happened to us, it is as if the sky has fallen on our heads," Loua told The Associated Press. Authorities are trying to establish who was responsible, Prime Minister Amadou Oury Bah said on national television. The National Alliance for Alternation and Democracy opposition coalition said the tournament was organized to drum up support for Doumbouya's "illegal and inappropriate" political ambitions. Doumbouya, who ousted then-President Alpha Conde in 2021, has been eyeing a possible run for the presidential election, for which the date has not been set. The transition charter put in place by his own regime does not allow him to run. Guinea is one of a number of West African countries - including Mali, Niger and Burkina Faso - where the military has taken power and delayed a return to civilian rule. Doumbouya said he was preventing the country from slipping into chaos and chastised the previous government for broken promises. He has, however, been criticized for not meeting the expectations that he raised. Guinea's leader announced three days of national mourning starting on Tuesday, in a presidential decree read on national television.Younger Asian Americans navigate something new to their generation: Taking up spaceCanada didn’t live up to its values on immigration in recent years, Carney says
NEW YORK (AP) — Matías Tarnopolsky will become president and CEO of the New York Philharmonic on Jan. 1 after six years heading the Philadelphia Orchestra, a hiring boosted by his long friendship with . Tarnopolsky's appointment was announced Monday. The 54-year-old, who has American, British and Argentine citizenship, fills a void created when Gary Ginstling quit in July just one season into the job. “He’s done a really wonderful job with Philadelphia, and one of the most important issues was that he has a very close relationship with Gustavo Dudamel,” philharmonic co-chairman Peter W. May said. “That was really the most important factor for us.” Born in Buenos Aires, Argentina, Tarnopolsky played clarinet and received bachelor’s and master’s degrees in music and musicology from King's College, London. A performance of Mahler’s Fifth Symphony by Leonard Bernstein and the Vienna Philharmonic at the 1987 BBC Proms had an especially memorable impact. He was the New York Philharmonic's vice president of artistic planning from December 2005 until August 2009, then spent nine years as executive director of Cal Performances at Berkeley until moving to Philadelphia in 2018. Cal hosted Dudamel and the Simón Bolívar Symphony Orchestra in several residencies. He called his return to the New York Philharmonic along with Dudamel a “full circle moment,” recalling hitting it off with the conductor during a work visit to Caracas. “I watched him work with the kids of the Simón Bolivar and was just blown away, and so we invited him to conduct the New York Philharmonic. So this is a story almost two decades in the making,” Tarnopolsky said in an interview. as executive director from Washington's National Symphony Orchestra. “Frankly, it just wasn’t a good fit from both Gary's perspective and our perspective," May told The Associated Press. "Matías clearly had significantly more experience than Gary has had in terms of leading one of the top orchestras in the country and we're quite confident that this is the right guy for the job.” Philharmonic co-chairman Oscar L. Tang said Tarnopolsky is aligned with the vision held by Dudamel and the board. “Gustavo says that he feels classical music is a human right and he wants to view classical music as a force for social development, social good,” Tang said. “These are some of the aspirations that Peter and I have for the New York Phil in terms of extending its role in the cultural and civic life of New York City and really the country and the world.” The New York Philharmonic in October 2022, announced . Borda said guest conductors have been engaged and a tour has been arranged for Dudamel's first season, with his approval, but much of the 2026-27 programming remains open. “Here’s a chance that comes along maybe once in a lifetime to author a completely new chapter for a great musical institution,” Tarnopolsky said. “The commitment here is to rededicate ourselves to ensuring the philharmonic’s place in the civic, cultural, musical, educational life of contemporary New York.” Ryan Fleur, the Philadelphia Orchestra's executive director, will become its interim president on Jan. 1, a role he held for eight months in 2018 between Allison Vulgamore's departure and Tarnopolsky's arrival. ___ This story corrects that Matías Tarnopolsky headed Philadelphia Orchestra six years. Ronald Blum, The Associated Press
No secrets as Bucs visit Dave Canales, Panthers for NFC South showdownBy JOSH BOAK WASHINGTON (AP) — Donald Trump loved to use tariffs on foreign goods during his first presidency. But their impact was barely noticeable in the overall economy, even if their aftershocks were clear in specific industries. The data show they never fully delivered on his promised factory jobs. Nor did they provoke the avalanche of inflation that critics feared. This time, though, his tariff threats might be different . The president-elect is talking about going much bigger — on a potential scale that creates more uncertainty about whether he’ll do what he says and what the consequences could be. “There’s going to be a lot more tariffs, I mean, he’s pretty clear,” said Michael Stumo, the CEO of Coalition for a Prosperous America, a group that has supported import taxes to help domestic manufacturing. The president-elect posted on social media Monday that on his first day in office he would impose 25% tariffs on all goods imported from Mexico and Canada until those countries satisfactorily stop illegal immigration and the flow of illegal drugs such as fentanyl into the United States. Those tariffs could essentially blow up the North American trade pact that Trump’s team negotiated during his initial term. Chinese imports would face additional tariffs of 10% until Beijing cracks down on the production of materials used in making fentanyl, Trump posted. Business groups were quick to warn about rapidly escalating inflation , while Mexican President Claudia Sheinbaum said she would counter the move with tariffs on U.S. products. House Democrats put together legislation to strip a president’s ability to unilaterally apply tariffs this drastic, warning that they would likely lead to higher prices for autos, shoes, housing and groceries. Sheinbaum said Wednesday that her administration is already working up a list of possible retaliatory tariffs “if the situation comes to that.” “The economy department is preparing it,” Sheinbaum said. “If there are tariffs, Mexico would increase tariffs, it is a technical task about what would also benefit Mexico,” she said, suggesting her country would impose targeted import duties on U.S. goods in sensitive areas. Related Articles House Democrats on Tuesday introduced a bill that would require congressional approval for a president to impose tariffs due to claims of a national emergency, a largely symbolic action given Republicans’ coming control of both the House and Senate. “This legislation would enable Congress to limit this sweeping emergency authority and put in place the necessary Congressional oversight before any president – Democrat or Republican – could indiscriminately raise costs on the American people through tariffs,” said Rep. Suzan DelBene, D-Wash. But for Trump, tariffs are now a tested tool that seems less politically controversial even if the mandate he received in November’s election largely involved restraining inflation. The tariffs he imposed on China in his first term were continued by President Joe Biden, a Democrat who even expanded tariffs and restrictions on the world’s second largest economy. Biden administration officials looked at removing Trump’s tariffs in order to bring down inflationary pressures, only to find they were unlikely to help significantly. Tariffs were “so new and unique that it freaked everybody out in 2017,” said Stumo, but they were ultimately somewhat modest. Trump imposed tariffs on solar panels and washing machines at the start of 2018, moves that might have pushed up prices in those sectors even though they also overlapped with plans to open washing machine plants in Tennessee and South Carolina. His administration also levied tariffs on steel and aluminum, including against allies. He then increased tariffs on China, leading to a trade conflict and a limited 2020 agreement that failed to produce the promised Chinese purchases of U.S. goods. Still, the dispute changed relations with China as more U.S. companies looked for alternative suppliers in other countries. Economic research also found the United States may have sacrificed some of its “soft power” as the Chinese population began to watch fewer American movies. The Federal Reserve kept inflation roughly on target, but factory construction spending never jumped in a way that suggested a lasting gain in manufacturing jobs. Separate economic research found the tariff war with China did nothing economically for the communities hurt by offshoring, but it did help Trump and Republicans in those communities politically. When Trump first became president in 2017, the federal government collected $34.6 billion in customs, duties and fees. That sum more than doubled under Trump to $70.8 billion in 2019, according to Office of Management and Budget records. While that sum might seem meaningful, it was relatively small compared to the overall economy. America’s gross domestic product is now $29.3 trillion, according to the Bureau of Economic Analysis. The total tariffs collected in the United States would equal less than 0.3% of GDP. The new tariffs being floated by Trump now are dramatically larger and there could be far more significant impacts. If Mexico, Canada, and China faced the additional tariffs proposed by Trump on all goods imported to the United States, that could be roughly equal to $266 billion in tax collections, a number that does not assume any disruptions in trade or retaliatory moves by other countries. The cost of those taxes would likely be borne by U.S. families, importers and domestic and foreign companies in the form of higher prices or lower profits. Former Biden administration officials said they worried that companies could piggyback on Trump’s tariffs — if they’re imposed — as a rationale to raise their prices, just as many companies after Russia’s invasion of Ukraine in 2022 boosted food and energy costs and gave several major companies the space to raise prices, according to their own earnings calls with investors. But what Trump didn’t really spell out is what might cause him to back down on tariffs and declare a victory. What he is creating instead with his tariff threats is a sense of uncertainty as companies and countries await the details to figure out what all of this could mean. “We know the key economic policy priorities of the incoming Trump administration, but we don’t know how or when they will be addressed,” said Greg Daco, chief U.S. economist at EY-Parthenon. AP writer Mark Stevenson contributed to this report from Mexico City.
Delaware judge reaffirms ruling that invalidated massive Tesla pay package for Elon MuskBy ROB GILLIES, Associated Press TORONTO (AP) — Prime Minister Justin Trudeau told Donald Trump that Americans would also suffer if the president-elect follows through on a plan to impose sweeping tariffs on Canadian products , a Canadian minister who attended their recent dinner said Monday. Trump threatened to impose tariffs on products from Canada and Mexico if they don’t stop what he called the flow of drugs and migrants across their borders with the United States. He said on social media last week that he would impose a 25% tax on all products entering the U.S. from Canada and Mexico as one of his first executive orders. Canadian Public Safety Minister Dominic LeBlanc, whose responsibilities include border security, attended a dinner with Trump and Trudeau at Trump’s Mar-a-Lago club on Friday. Trudeau requested the meeting in a bid to avoid the tariffs by convincing Trump that the northern border is nothing like the U.S. southern border with Mexico . “The prime minister of course spoke about the importance of protecting the Canadian economy and Canadian workers from tariffs, but we also discussed with our American friends the negative impact that those tariffs could have on their economy, on affordability in the United States as well,” LeBlanc said in Parliament. If Trump makes good on his threat to slap 25% tariffs on everything imported from Mexico and Canada, the price increases that could follow will collide with his campaign promise to give American families a break from inflation. Economists say companies would have little choice but to pass along the added costs, dramatically raising prices for food, clothing, automobiles, alcohol and other goods. The Produce Distributors Association, a Washington trade group, said last week that tariffs will raise prices for fresh fruit and vegetables and hurt U.S. farmers when the countries retaliate. Canada is already examining possible retaliatory tariffs on certain items from the U.S. should Trump follow through on the threat. After his dinner with Trump, Trudeau returned home without assurances the president-elect will back away from threatened tariffs on all products from the major American trading partner. Trump called the talks “productive” but signaled no retreat from a pledge that Canada says unfairly lumps it in with Mexico over the flow of drugs and migrants into the United States. “The idea that we came back empty handed is completely false,” LeBlanc said. “We had a very productive discussion with Mr. Trump and his future Cabinet secretaries. ... The commitment from Mr. Trump to continue to work with us was far from empty handed.” Joining Trump and Trudeau at dinner were Howard Lutnick, Trump’s nominee for commerce secretary, North Dakota Gov. Doug Burgum, Trump’s pick to lead the Interior Department, and Mike Waltz, Trump’s choice to be his national security adviser. Canada’s ambassador to the U.S., Kirsten Hillman, told The Associated Press on Sunday that “the message that our border is so vastly different than the Mexican border was really understood.” Hillman, who sat at an adjacent table to Trudeau and Trump, said Canada is not the problem when it comes to drugs and migrants. On Monday, Mexico’s president rejected those comments. “Mexico must be respected, especially by its trading partners,” President Claudia Sheinbaum said. She said Canada had its own problems with fentanyl consumption and “could only wish they had the cultural riches Mexico has.” Related Articles National Politics | Young men swung to the right for Trump after a campaign dominated by masculine appeals National Politics | In final month of the session, Congress looks to clean up loose ends, prepare for Trump National Politics | Democrats still don’t agree on the seriousness of their political problem after election defeat National Politics | Recess appointments could put Trump at odds with conservatives on the Supreme Court National Politics | Under Trump, many states might pursue Medicaid work requirements Flows of migrants and seizures of drugs at the two countries’ border are vastly different. U.S. customs agents seized 43 pounds of fentanyl at the Canadian border during the last fiscal year, compared with 21,100 pounds at the Mexican border. Most of the fentanyl reaching the U.S. — where it causes about 70,000 overdose deaths annually — is made by Mexican drug cartels using precursor chemicals smuggled from Asia. On immigration, the U.S. Border Patrol reported 1.53 million encounters with migrants at the southwest border with Mexico between October 2023 and September 2024. That compares to 23,721 encounters at the Canadian border during that time. Canada is the top export destination for 36 U.S. states. Nearly $3.6 billion Canadian (US$2.7 billion) worth of goods and services cross the border each day. About 60% of U.S. crude oil imports are from Canada, and 85% of U.S. electricity imports as well. Canada is also the largest foreign supplier of steel, aluminum and uranium to the U.S. and has 34 critical minerals and metals that the Pentagon is eager for and investing for national security. Click to share on Facebook (Opens in new window) Click to share on X (Opens in new window) Most Popular 1 dead, 2 seriously injured in Newport News triple shooting, police say 1 dead, 2 seriously injured in Newport News triple shooting, police say Biden pardons his son Hunter despite previous pledges not to Biden pardons his son Hunter despite previous pledges not to German restaurant Deutsche Ecke opens in Newport News German restaurant Deutsche Ecke opens in Newport News Former Hampton High football coach Mike Smith highlights latest Virginia Hall of Fame inductees Former Hampton High football coach Mike Smith highlights latest Virginia Hall of Fame inductees Al Roker speaks out after Macy’s Thanksgiving Day Parade chair mishap Al Roker speaks out after Macy’s Thanksgiving Day Parade chair mishap Underground fire at Williamsburg Premium Outlets extinguished Underground fire at Williamsburg Premium Outlets extinguished Dad kills wife, shoots 21-year-old daughter on the phone with 911, police say Dad kills wife, shoots 21-year-old daughter on the phone with 911, police say Teel: Chaos abounds in college football, but not when it comes to Virginia Tech vs. UVA Teel: Chaos abounds in college football, but not when it comes to Virginia Tech vs. UVA Editorial: New executive director set to lead Fort Monroe into the future Editorial: New executive director set to lead Fort Monroe into the future New Kent wants public input on future of Makemie Woods New Kent wants public input on future of Makemie Woods Trending Nationally A young Coloradan learning to live with long COVID turns to TikTok to educate about chronic illness US Senate inquiry into Chicago’s housing of migrants at airports likely to heat up after Republican election wins Homes vs. beaches: Court makes key decision in battle over California seawall construction amid ocean rise Fruit trees and ‘generational learning’ turn this California city into a parrot paradise as temperatures drop Rapper Tekashi 6ix9ine’s legal troubles expand with two South Florida lawsuits
'Dancing with the Stars' winner Joey Graziadei 'blacked out' when he got the Mirrorball
New York woman draws closer to solving 44-year-old mystery of her grandparents' disappearanceKosovo arrests blast suspects, Serbia denies involvement
The Right Private Wealth Management Assistance ServicesThe Maharashtra Public Works Department (PWD) is using Artificial Intelligence for road surveys in Latur, which officials said may be the first of its kind in the state. The AI-based project is underway in Udgir and funding of ₹ 1.99 crore has been made available by the District Planning and Development Council (DPDC), said PWD executive engineer Rohan Jadhav on Sunday. It involves a digital survey of roads to give details on quality, sequential numbering, traffic density, which will help PWD carry out better construction and maintenance, he said. The official added that Pune-based Rasta.Ai, a road maintenance and asset management firm, is carrying out the work. Read more: An AI company is raising $10 billion in a single round
2025 Audi A6 e-tron accelerates to 100 km/h in 4.5 seconds
“An educated citizenry is a vital requisite for our survival as a free people.” – Thomas Jefferson I read a post about an English teacher who was taking his students on a field trip to Henry David Thoreau’s cabin. Valuable. Thoreau was our most famous nature writer. And field trips can enrich us. One father, however, was furious. Why? Background information referenced “transcendentalism,” a 19 th century philosophical movement about nature and individualism. This father objected to the prefix “trans,” falsely assuming this was about transsexual “indoctrination.” The United States has a reading problem. Studies show that half of Americans read at a sixth-grade level or below. We need higher standards than that. Higher levels include vocabulary, but also critical thinking – facts versus opinions, inferences, logic. But given the new administration and the proposed dismantling of the Department of Education, standards will not rise; many students in our community, North Dakota, Minnesota, will be hurt. As an English instructor at community colleges, I received notices that some students needed special support. Most came from K – 12 schools that included, by law, an IEP (Individualized Education Program), a legal document under federal law to ensure students receive special ed support. The document is developed with the child’s parents and school employees. This free service would probably be lost for students in varied categories, such as those with hearing and speech impairment, autism, visual impairment, dyslexia and ADHD. It can also include students with diabetes or sickle cell anemia, along with gifted students. The Department of Education also investigates sexual misconduct and civil rights violations. If we rely on states, on “school choice” and vouchers – tools to destroy unions and academic freedom – we have even more uneven standards to help ensure student protection, when we need stronger, more equitable standards. My parents thankfully believed in good public schools. I am grateful for good teachers and how they enriched my life. Unlike some of my college students, I learned about fractions and the roots of the Civil War. I recall art and music classes. In second grade, a French woman gave us weekly French lessons. And, yes, there were field trips to Detroit’s great museums, and the Detroit Symphony, where we learned the different sections of the orchestra, from strings to woodwinds. It helped me to learn alongside a diverse population. But the greatest gift was reading. Starting with phonics, (studies find it better than “whole language”), through reading I could see the world, its variety. Now many Ivy League students don’t know how to read a book. Studies show reading develops intelligence, empathy, a healthy skepticism, including analysis and questioning. It can produce lifelong learners and better citizens. Christian author Philip Yancey was asked why he did not conform to his racist upbringing. He answered, “I was a reader.” With school choice, we leave too much power to sometimes biased parents. My parents were involved – my dad headed the PTA. Both met teachers, but my mother was plagued by superstition and, later, my “educated” sister would forbid her daughter from joining a field trip to a planetarium because she thought it an introduction to astrology. Education, and especially reading, needs an upgrade. STEM (science, technology, engineering, and math) is good, but as the saying goes “reading is fundamental” and eliminating the Department of Education is not the way to improve it.Australia is about to find out if stopping under-16s accessing social media will protect against harmful content or stifle creativity and block opportunity
NoneNone
NoneSEVENTEEN years on from the murder of Jeffrey Hannan, his daughter Nikita, 18 - who was just a baby when her father was killed - speaks about the impact of the loss and not having her dad to walk her down the isle. “I'm engaged now. I'm happy. I'm living with my father's death every day of the week but I'm trying to keep strong for him and for me and for my family,” said Nikita. The teenager got engaged on her 18th birthday this year, on October 29, when her fiance surprised her by getting down on one knee as she was touching up her makeup. Despite this exciting step forward, Nikita said: “Your dad's meant to give you away, and then you're meant to have your dad and daughter dance. I'm sure people do that... That's what's gonna kill me.” Jeffrey was 19 years old - one year older than Nikita is now - when his body was found on November 22, 2007 at approximately 10:40am in O’Malley Park, Southill, Limerick. He suffered multiple injuries to his head and upper body. “I have pictures, I have his name tattooed, that's how I kind of know he's there with me. I have his name tattooed onto my hand since I'm 15 so he comes everywhere with me.” Looking ahead to the festive season when people are usually joyful, Nikita explained what a typical Christmas Day is like for her. "I'll get up and I'll drink and I'll keep drinking until Christmas is over because I can't sit there.” Nikita was raised by her grandparents and found it difficult growing up without her dad. She recalled going to a park with her grandmother and seeing other children being pushed on the swings by their parents. “It was just hard that I couldn't have that.” She also recalled other children's fascination with the material side of Christmas during her childhood and told them: "It's not about what you have at Christmas, it's about who you have. I said, 'do you know what I would give to have what you have at home'?” READ MORE: NCW Women’s Shed break tradition and bring politics to the table ahead of General Election She added that her father is in the grave and that he should be with his family. “He didn't get a chance in life,” she remarked. Nikita said Jeffery had a “heart of gold” and that he didn't deserve to be killed. He enjoyed listening to clubland music, particularly Timbaland's 'The Way I Are' which Jeffrey sang to Nikita when she was a baby. Nikita has suffered quite badly with her mental health in the past and has found life tough without her dad. She said she was “really low” and that her mental health was very bad in her teens. She was diagnosed with PTSD and anxiety and explained that she's been “doubly grieving” all her life. “I've come so far, and I didn't think I'd be able. When you're in that mindset, you don't think you'll be able to get out of it. “It's like you're trapped and you're in a bubble and are trying to get out of that bubble, and no one can hear you screaming... I turned my life around,” she said. She stated that it would bring her a sense of “relief” and “a lot of peace” to get justice for her dad and family and to know that the person who killed Jeffrey isn't “just walking free” like they have been. “The fact that he got murdered and I have to go to look at the newspapers and see him... and, obviously, my granddad was on Crime Call, like, I was often on the radio myself a few times when I was younger.” She said her grandmother will die “heartbroken” if they don't get justice. Gardaí are renewing their appeal for information on Jeffrey's murder. The investigation is being led by a Senior Investigating Officer from the Roxboro Road garda station.
China's Xi to lead Macau handover anniversary celebrations
The D-8 Summit in Egypt, forging a path to peaceful coexistence and regional stabilityPortland, Oregon, swears in new government and mayor who campaigned to end homelessnessNEW YORK , Dec. 2, 2024 /PRNewswire/ -- Report with the AI impact on market trends - The global active pharmaceutical ingredients market size is estimated to grow by USD 86.47 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 6.73% during the forecast period. Evolving api manufacturing scenario in developing scenario is driving market growth, with a trend towards paradigm shift in api manufacturing. However, high investment cost and concern of huge loss poses a challenge. Key market players include AbbVie Inc., Amneal Pharmaceuticals Inc., Apotex Inc., Aurobindo Pharma Ltd., Cadila Pharmaceuticals Ltd., Cambrex Corp., Cipla Ltd., Dr Reddys Laboratories Ltd., GlaxoSmithKline Plc, Indena S.p.A., INTERNATIONAL CHEMICAL INVESTORS S.E., Koninklijke DSM NV, Lupin Ltd., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc.. Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF Active Pharmaceutical Ingredients Market Scope Report Coverage Details Base year 2023 Historic period 2018 - 2022 Forecast period 2024-2028 Growth momentum & CAGR Accelerate at a CAGR of 6.73% Market growth 2024-2028 USD 86.47 billion Market structure Fragmented YoY growth 2022-2023 (%) 6.24 Regional analysis Asia, North America, Europe, and Rest of World (ROW) Performing market contribution Asia at 52% Key countries US, Germany, China, India, and Japan Key companies profiled AbbVie Inc., Amneal Pharmaceuticals Inc., Apotex Inc., Aurobindo Pharma Ltd., Cadila Pharmaceuticals Ltd., Cambrex Corp., Cipla Ltd., Dr Reddys Laboratories Ltd., GlaxoSmithKline Plc, Indena S.p.A., INTERNATIONAL CHEMICAL INVESTORS S.E., Koninklijke DSM NV, Lupin Ltd., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc. Market Driver Pharmaceutical companies have historically relied on in-house capabilities for API discovery, development, and manufacturing. However, the last few decades have seen a shift towards outsourcing these processes to Contract Manufacturing Organizations (CMOs) or other drug manufacturing entities. Initially, this was driven by necessity, but it has since evolved into an effective collaboration model. The value chain for APIs has expanded from early-stage intermediates to advanced intermediates and final dosage forms. The decision to outsource an API depends on industry trends, cost of new technologies, and internal capacity. Small organizations particularly benefit from outsourcing due to cost savings and time efficiencies. Outsourcing enables companies to meet aggressive development timelines and capitalize on supply chain efficiencies, contributing to the growth of the active pharmaceutical ingredients market. The outsourcing trend is expected to continue as companies focus on reducing time to market and increasing innovation. The Active Pharmaceutical Ingredients (API) market is experiencing significant trends in various sectors. In formulation development, excipients play a crucial role, with companies like Chasse-sur-Rhône and NovasepPharmaZell Group leading the way. Teva Pharmaceutical and MEDinCell are making strides in Schizophrenia and chronic diseases research. Counterfeit drugs pose a threat, driving the need for increased investment in research and development. Infectious diseases, genetic disorders, cardiovascular diseases, and chronic disorders continue to be major focus areas. Biologics and biosimilars are on the rise, with CuraTeQ Biologics, Mendus AB, GenScript ProBio, and GeneCraft leading the charge. Key APIs include Acetaminophen, Artemisinin, Saxagliptin, Sodium Chloride, Ibuprofen, Losartan Potassium, Enoxaparin Sodium, Rufinamide, Naproxen, and Tamoxifen. Prescription drugs in Cardiology, CNS Neurology, and Oncology are over-clinical, with large molecule and small molecule APIs in high demand. Captive and merchant API manufacturers like Eurofins play essential roles in supplying these essential ingredients. Key APIs include Acetaminophen, Artemisinin, Saxagliptin, Sodium Chloride, Ibuprofen, Losartan Potassium, Enoxaparin Sodium, Rufinamide, Naproxen, and Tamoxifen. The market for prescription drugs in Cardiology, CNS Neurology, and Oncology remains over-clinical, with large molecule and small molecule APIs in high demand. Captive and merchant API manufacturers like Eurofins play essential roles in supplying these essential ingredients. Some of the major APIs in focus are Acetaminophen, Artemisinin, Saxagliptin, Sodium Chloride, Ibuprofen, Losartan Potassium, Enoxaparin Sodium, Rufinamide, Naproxen, and Tamoxifen. The market for prescription drugs in Cardiology, CNS Neurology, and Oncology remains over-clinical, with large molecule and small molecule APIs in high demand. Captive and merchant API manufacturers like Eurofins play essential roles in supplying these essential ingredients. In the API market, trends include a focus on excipients, biologics and biosimilars, and a continued emphasis on research and development to combat counterfeit drugs and address the needs of chronic diseases such as Schizophrenia, infectious diseases, genetic disorders, cardiovascular diseases, and chronic disorders. Key APIs include Acetaminophen, Artemisinin, Saxagliptin, Sodium Chloride, Ibuprofen, Losartan Potassium, Enoxaparin Sodium, Rufinamide, Naproxen, and Tamoxifen, with applications in prescription drugs for Cardiology, CNS Neurology, and Oncology. Captive and merchant API manufacturers like Eurofins play essential roles in supplying these ingredients. Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution! Market Challenges Discover how AI is revolutionizing market trends- Get your access now! Segment Overview This active pharmaceutical ingredients market report extensively covers market segmentation by 1.1 Captive APIs- The captive API manufacturing segment holds the largest share in the global Active Pharmaceutical Ingredients (API) market due to the increasing development of biopharmaceutical products and the emphasis on quality control. The healthcare industry's focus on affordable healthcare services has driven the demand for low-cost APIs, leading some innovators to outsource to Contract Manufacturing Organizations (CMOs). However, the expiry of patents on blockbuster drugs has slowed down the growth of the API market for these drugs. In contrast, the API market for generic drugs is booming due to the increasing production capacity. The development of biopharmaceutical products requires significant investment and the risk of financial loss due to small variations in APIs, making in-house capabilities essential for innovators. Regulatory authorities' emphasis on quality control further increases the dependency on in-house API manufacturing. Major pharmaceutical companies, such as Pfizer, Novartis, Sanofi, and GlaxoSmithKline Plc, are investing in in-house API capabilities to drive the growth of the captive API segment and expand the global API market. Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics Research Analysis The Active Pharmaceutical Ingredients (API) market encompasses the production and supply of Excipients, the non-active components used in pharmaceutical formulations, and the Active Pharmaceutical Ingredients themselves. These substances play a crucial role in the therapeutic effect of medicines. The market caters to various therapeutic areas such as Chasse-sur-Rhône for Schizophrenia, Chronic diseases, Infectious diseases, Genetic disorders, Cardiovascular diseases, and Chronic disorders. The market is driven by research and investment in Biologics, Biosimilars, Cancer, Oncology drug research, Diabetes, Small Molecule, and Large Molecule APIs. The market also addresses the challenge of Counterfeit drugs, ensuring the production of high-quality APIs. Notable sub-segments include Captive API Manufacturer and Merchant API Manufacturer. Examples of APIs include Acetaminophen, Artemisinin, and many others used in treating diverse medical conditions. Market Research Overview The Active Pharmaceutical Ingredients (API) market encompasses the production and supply of Excipients, the non-active components used in pharmaceutical formulations, and APIs, the essential substances that provide therapeutic effects. The market caters to various therapeutic areas such as Schizophphrenia, Chronic diseases, Infectious diseases, Genetic disorders, Cardiovascular diseases, and Chronic disorders. APIs are integral to Biologics, Biosimilars, and Oncology drug research, including for treatments in Cardiology, CNS Neurology, Oncology, Orthopedic, Endocrinology, Pulmonology, Nephrology, Ophthalmology, and other therapeutic applications. Key challenges in the market include counterfeit drugs, lack of demand, and regulatory compliance. Notable APIs include Acetaminophen, Artemisinin, Saxagliptin, Sodium Chloride, Ibuprofen, Losartan Potassium, Enoxaparin Sodium, Rufinamide, Naproxen, Tamoxifen, and Prescription Drugs like Over-the-counter (OTC) and Clinical trial drugs. Major players in the market include Captive API Manufacturers and Merchant API Manufacturers. Some notable companies are Chasse-sur-Rhône, Teva Pharmaceutical, MEDinCell, Schizophrenia, CuraTeQ Biologics, Mendus AB, GenScript ProBio, GeneCraft, NovasepPharmaZell Group, and Eurofins. APIs are used in the production of Small Molecule and Large Molecule drugs, with key examples being Acetaminophen (Small Molecule) and Biologics (Large Molecule). Other significant APIs include Artemisinin (Antimalarial), Saxagliptin (Diabetes), Sodium Chloride (Pharmaceutical Excipient), Ibuprofen (Analgesic), Losartan Potassium (Antihypertensive), Enoxaparin Sodium (Anticoagulant), Rufinamide (Anticonvulsant), Naproxen (Analgesic), and Tamoxifen (Antiestrogen). The market is driven by research and investment in various therapeutic areas, including Cancer, Oncology drug research, and Diabetes. Key diseases targeted include Schizophrenia, Chronic diseases, Infectious diseases, Genetic disorders, Cardiovascular diseases, and Chronic disorders. Some notable APIs in the market include Acetaminophen (Analgesic and Antipyretic), Artemisinin (Antimalarial), Saxagliptin (Diabetes), Sodium Chloride (Pharmaceutical Excipient), Ibuprofen (Analgesic and Anti-inflammatory), Losartan Potassium (Antihypertensive), Enoxaparin Sodium (Anticoagulant), Rufinamide (Anticonvulsant), Naproxen (Analgesic and Anti-inflammatory), and Tamoxifen (Antiestrogen). The market is segmented into Small Molecule and Large Molecule APIs. Small Molecule APIs are typically synthesized using chemical reactions, while Large Molecule APIs are produced using biotechnological processes. The market is also influenced by various factors such as regulatory compliance, counterfeit drugs, and the shift towards personalized medicine and biosimilars. Regulatory compliance is crucial in ensuring the safety and efficacy of APIs, while the rise of counterfeit drugs poses a significant challenge to market growth. The shift towards personalized medicine and biosimilars is expected to create new opportunities for API manufacturers. Some notable companies in the market include Chasse-sur-Rhône, Teva Pharmaceutical, MEDinCell, Schizophrenia, CuraTeQ Biologics, Mendus AB, GenScript ProBio, GeneCraft, NovasepPharmaZell Group, and Eurofins. Chasse-sur-Rhône is a leading player in the API market, with a focus on the production of Small Molecule APIs. Teva Pharmaceutical is another major player, with a strong presence in both Small Molecule and Large Molecule APIs. MEDinCell specializes in the production of Large Molecule APIs, while Schizophrenia focuses on the development and production of APIs for the treatment of Schizophrenia and other CNS disorders. CuraTeQ Biologics, Mendus AB, GenScript ProBio, GeneCraft, and NovasepPharmaZell Group are other notable players in the market, with a focus on the production of Large Molecule APIs. Eurofins is a leading provider of contract research services, including API development and manufacturing. The market for APIs is expected to grow significantly in the coming years, driven by research and investment in various therapeutic areas, including Cancer, Oncology drug research, and Diabetes. The increasing prevalence of chronic diseases, such as cardiovascular diseases and diabetes, is also expected to fuel market growth. Some notable APIs in the market include Acetaminophen, Artemisinin, Saxagliptin, Sodium Chloride, Ibuprofen, Losartan Potassium, Enoxaparin Sodium, Rufinamide, Naproxen, and Tamoxifen. Acetaminophen is a widely used analgesic and antipyretic, while Artemisinin is an essential component in the treatment of malaria. Saxagliptin is a popular diabetes drug, while Sodium Chloride is a common pharmaceutical excipient. Ibuprofen is an analgesic and anti-inflammatory drug, while Losartan Potassium is an antihypertensive. Enoxaparin Sodium is an anticoagulant, Rufinamide is an anticonvulsant, Naproxen is an analgesic and anti-inflammatory drug, and Tamoxifen is an antiestrogen. The market for APIs is segmented into Small Molecule and Large Molecule APIs. Small Molecule APIs are typically synthesized using chemical reactions, while Large Molecule APIs are produced using biotechnological processes. Small Molecule APIs are typically less complex and can be produced in larger quantities, making them more cost-effective. However, they may have limited therapeutic effects and may require the use of multiple APIs to achieve the desired therapeutic outcome. Large Molecule APIs, on the other hand, are more complex and may require more specialized production processes. They are typically more expensive to produce but may offer more targeted therapeutic effects. The market for APIs is influenced by various factors, including regulatory compliance, counterfeit drugs, and the shift towards personalized medicine and biosimilars. Regulatory compliance is crucial in ensuring the safety and efficacy of APIs, while the rise of counterfeit drugs poses a significant challenge to market growth. The shift towards personalized medicine and biosimilars is expected to create new opportunities for API manufacturers. The market for APIs is expected to grow significantly in the coming years, driven by research and investment in various therapeutic areas, including Cancer, Oncology drug research, and Diabetes. The increasing prevalence of chronic diseases, such as cardiovascular diseases and diabetes, is also expected to fuel market growth. Some of the key challenges facing the API market include regulatory compliance, counterfeit drugs, and the shift towards personalized medicine and biosimilars. Regulatory compliance is crucial in ensuring the safety and efficacy of APIs, while the rise of counterfeit drugs poses a significant challenge to market growth. The shift towards personalized medicine and biosimilars is expected to create new opportunities for API manufacturers. Regulatory compliance is a major challenge for API manufacturers, as they must adhere to strict regulations to ensure the safety and efficacy of their products. This includes compliance with Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP), as well as regulatory requirements for the registration and approval of APIs. Counterfeit drugs are another significant challenge for the API market, as they can pose a risk to patient safety and undermine the credibility of legitimate API manufacturers. Counterfeit drugs may contain substandard or contaminated APIs, which can lead to adverse reactions or ineffective treatments. The shift towards personalized medicine and biosimilars is expected to create new opportunities for API manufacturers, as these treatments require the production of more complex APIs. Personalized medicine and biosimilars offer more targeted therapeutic effects and can reduce the cost of treatments, making them more accessible to patients. Some of the key trends in the API market include the increasing use of biotechnological processes for the production of Large Molecule APIs, the growing demand for biosimilars and personalized medicines, and the increasing focus on regulatory compliance and quality control. The increasing use of biotechnological processes for the production of Large Molecule APIs is a significant trend in the market, as these processes offer more targeted therapeutic effects and can reduce the production costs of complex APIs. Biotechnological processes involve the use of living organisms or cells to produce APIs, which can result in more complex and effective therapeutic agents. The growing demand for biosimilars and personalized medicines is another key trend in the API market, as these treatments offer more targeted therapeutic effects and can reduce the cost of treatments. Biosimilars are generic versions of biologic drugs, while personalized medicines are tailored to the individual needs of patients based on their genetic makeup or other factors. The increasing focus on regulatory compliance and quality control is also a significant trend in the API market, as regulatory agencies continue to tighten their requirements for the safety and efficacy of APIs. This includes the implementation of stricter GMP and GLP regulations, as well as the use of advanced technologies for quality control and testing. In conclusion, the API market is a dynamic and growing industry, driven by research and investment in various therapeutic areas and the increasing prevalence of chronic diseases. The market is segmented into Small Molecule and Large Molecule APIs, with each offering unique advantages and challenges. The market is influenced by various factors, including regulatory compliance, counterfeit drugs, and the shift towards personalized medicine and biosimilars. The increasing use of biotechnological processes for the production of Large Molecule APIs, the growing demand for biosimilars and personalized medicines, and the increasing focus on regulatory compliance and quality control are some of the key trends in the market. Table of Contents: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: media@technavio.com Website: www.technavio.com/ View original content to download multimedia: https://www.prnewswire.com/news-releases/active-pharmaceutical-ingredients-market-to-grow-by-usd-86-47-billion-2024-2028-driven-by-evolving-api-manufacturing-with-ai-driving-market-transformation---technavio-302319403.html SOURCE Technavio
- Previous:
- Next: 2 section fishing rod
